Mumbai-based pharmaceutical company will be soon launching Merck Sharp Dohme and Ridgrback’s molnupiravir pill, the first oral antiviral Covid treatment, as brand name ‘Molxvir’ in India
India’s drug regulator, the Drugs Controller General of India (DCGI), is currently reviewing clinical data of anti-Covid pill for the treatment among adults.
Sun Pharmaceutical Industries said that they are waiting for the approval from the drug regulator.
Sun Pharma India Business CEO Kirti Ganorkar Said :
Molnupiravir has already been approve by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID -19 infection among adults.
It is under review by the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA).
Sun Pharma had sign a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir in India and to over 100 low and middle-income countries (LMICs).
Molnupiravir, which is taken orally, reduces the ability of SARS CoV 2, the virus that causes COVID-19 to multiply in the body.
Pills does this by increasing the number of alterations (mutations) in the virus’s genetic material (known as RNA), in a way that impairs the ability of SARS-CoV-2 to multiply.
THANK YOU FOR READING.